African tech startups secured a record $1.64 billion in debt financing last year, a pivotal shift as mature firms seek alternative capital to fuel growth while retaining ownership, according to a new industry report.
With major indices treading water after the Fed's steady rates, savvy investors are turning to overlooked small-cap stocks where insider buying signals conviction. We examine three companies where executives are backing their firms with their own capital.
Amazon is reportedly negotiating a landmark investment of up to $50 billion in OpenAI, a move that would reshape the AI landscape and intensify its cloud rivalry with Microsoft and Google. The potential deal highlights the soaring costs of competing in generative AI and could redefine Amazon Web Services' strategy.
Amid a year of both share sales and purchases by company executives, a significant insider investment by Andrew Teich signals underlying confidence in Resideo Technologies' future, even as the firm navigates a challenging financial landscape.
Nomura Holdings reported robust Q3 results, with its four main divisions hitting an 18.5-year profit high and ROE consistently exceeding targets. However, losses in its digital asset unit tempered overall gains, prompting the firm to announce a significant share repurchase program.
A surge in housing supply, particularly across Sun Belt states, is creating prime conditions for homebuyers, with new research highlighting metros where inventory levels tip the scale in the buyer's favor.
Reports of U.S. officials meeting with Alberta independence advocates have ignited a diplomatic row, as Canada's western province weighs a contentious push for sovereignty with an eye toward Washington.
Shares of life sciences toolmaker Qiagen (NYSE:QGEN) have shown renewed momentum, gaining over 12% in the past month. This surge brings the company's valuation into sharp focus, with analysts divided between near-term earnings multiples and long-term cash flow projections.
Deutsche Bank and its asset manager DWS are in preliminary talks to acquire a significant minority stake in Fosun-owned Frankfurter Leben, signaling a strategic reversal a decade after exiting the sector.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Real Matters Inc. (TSE: REAL) kicked off its 2026 fiscal year with robust double-digit revenue growth and a return to profitability, defying typical seasonal headwinds. The company's performance was fueled by market share gains, new client launches, and improved operational efficiency across its U.S. and Canadian segments.
While market volatility rattles investors, Volvere plc (LON:VLE) has quietly engineered a remarkable three-year run, with its share price soaring 148%. We examine the fundamentals behind the surge and ask if the momentum can hold.
The Horatio Alger Award bestowed upon ResMed founder Dr. Peter Farrell underscores the company's decades-long leadership in sleep and respiratory care, bringing its financial performance and competitive strategy into sharper focus for investors.
Microsoft's second-quarter earnings smashed expectations, fueled by a 26% surge in cloud revenue that crossed the $50 billion mark for the first time. The tech giant's aggressive AI investments are now driving significant growth across its enterprise stack.
Mitsubishi Corporation and U.S.-based Aethon Energy have announced a strategic global alliance aimed at co-developing projects across liquefied natural gas (LNG), carbon capture, geothermal energy, and digital infrastructure, marking a significant step in the Japanese conglomerate's lower-carbon expansion.
Cardinal Energy Ltd. (TSX:CJ) has successfully upsized its bought deal financing to CA$95.15 million, capitalizing on robust investor appetite. The proceeds are earmarked to accelerate development of its key Reford 2 thermal oil project and strengthen its balance sheet, even as its valuation metrics present a complex picture for investors.
Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.
The medical technology giant reported double-digit organic sales growth and robust profitability for 2025, driven by record installations of its Mako surgical robots. While projecting continued strength for 2026, management acknowledged incremental tariff pressures but expressed confidence in the company's ability to sustain margin expansion.
Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.
Freedom Capital Markets has lowered its price target for Li Auto (NASDAQ: LI) from $34 to $25, citing a mixed quarterly performance and a challenging outlook as China's electric vehicle sector grapples with a fierce price war and softening demand.
